AI summary · may contain errors
Gallbladder and biliary diseases increased globally from 1990 to 2023, with prevalence rising to 264.4 million and DALYs to 8.2 million despite declining age-standardised rates.
- Open access
- 5 cites
Moving in Clinical Cancer Research, Hepatology, Journal of Clinical Oncology, Journal of Hepatology, Oncogene, Annals of Oncology, Gastroenterology and Genome Medicine.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Gallbladder and biliary diseases increased globally from 1990 to 2023, with prevalence rising to 264.4 million and DALYs to 8.2 million despite declining age-standardised rates.
AI summary · may contain errors
In a single-center phase II trial in 42 patients with advanced biliary cancer, pembrolizumab plus GM-CSF achieved a confirmed ORR of 12% (95% CI, 4–26).
AI summary · may contain errors
FGFR2b, an alternatively spliced isoform of FGFR2, is a prevalent membrane cell-surface target in intrahepatic cholangiocarcinoma, present in 88.6% (institutional) and 88.2% (TCGA).
AI summary · may contain errors
Adding toripalimab (PD-1 blockade) to modified FOLFIRINOX improves event-free survival in randomized phase II patients with borderline resectable or locally advanced pancreatic cancer, median 11.1 vs 9.6 months.
AI summary · may contain errors
Cholangiocarcinomas show biologically distinct molecular subtypes that are not aligned with intrahepatic, perihilar, and distal surgical categories, including actionable targets like FGFR2 fusions and IDH1/2 mutations.
AI summary · may contain errors
A European-ancestry GWAS of 2366 cholangiocarcinoma cases and 11,750 controls identifies a new genome-wide significant variant, rs535777 (OR=1.44), near HLA-DRB1/DQA1.
AI summary · may contain errors
In HER2-positive advanced biliary tract cancer, a first-line trastuzumab+nivolumab plus gemcitabine/cisplatin regimen achieved a 55% objective response rate among 40 participants.
AI summary · may contain errors
Derazantinib 300 mg once daily produced clinically meaningful responses in previously treated advanced intrahepatic cholangiocarcinoma with FGFR2 fusions, with ORR 22.3% and median PFS 8.1 months.
AI summary · may contain errors
Cisplatin plus gemcitabine in the adjuvant setting for resected biliary tract cancer did not statistically improve disease-free survival versus capecitabine (25.7 vs 17.9 months).
AI summary · may contain errors
Tovecimig plus paclitaxel improved RECIST v1.1 objective response rate and progression-free survival versus paclitaxel alone in 168 patients with advanced biliary tract cancer, with ORR 18.0% vs 5.3%.
AI summary · may contain errors
Zenocutuzumab produced an investigator-assessed overall response rate of 36.8% (95% CI 16.3–61.6) in 19 advanced NRG1+ cholangiocarcinoma patients.
AI summary · may contain errors
Adjuvant S-1 after resection for biliary tract cancer yields sustained 5-year overall survival of 64% versus 52% with observation (HR 0.72, one-sided P=.01).
AI summary · may contain errors
A multi-kingdom, functional gut microbiota panel distinguishes cholangiocarcinoma from hepatocellular carcinoma with an AUC of 99.74% and a 11.11% false positive rate.
AI summary · may contain errors
In 46 first-line metastatic pancreatic ductal adenocarcinoma patients, the ICSBR regimen achieved a 78.3% 6-month progression-free survival rate, exceeding the 60% target.
AI summary · may contain errors
In 31 patients with advanced biliary tract cancer receiving rucaparib plus nivolumab maintenance, the 4-month progression-free survival rate was 54.8% (95% CI 36–72.7), not meeting the primary target.
AI summary · may contain errors
Pancreatic adenosquamous carcinoma shows subtype-specific spatial transcriptomic organization, with immune infiltrates closest to squamous regions and farthest from glandular regions.
AI summary · may contain errors
For advanced biliary tract cancer, ASCO’s 2026.1.0 living guideline recommends broad tissue DNA/RNA NGS at diagnosis and reserves plasma liquid biopsy mainly for when tissue is unavailable.
AI summary · may contain errors
Targeted therapies for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements show meaningful response rates and durable disease control.
AI summary · may contain errors
In biliary tract cancer patients, rising EGFR and MET CNV scores during first-line systemic anti-cancer treatment predict worse time to progression and overall survival.
AI summary · may contain errors
In advanced biliary tract cancer, ctDNA profiling detects actionable genomic alterations faster (8 vs. 27 days) and more often (90% vs. 50%) than tissue, with high concordance.
AI summary · may contain errors
ctDNA NGS profiling in 10,937 patients with advanced biliary tract cancers detects ESCAT actionable genomic alterations at rates comparable to tissue testing, with faster turnaround.
AI summary · may contain errors
In cholangiocarcinoma, intrahepatic, perihilar, and distal anatomic subtypes are distinct tumor entities, not one disease, with differences spanning biology and clinical behavior.
AI summary · may contain errors
Actionable molecular alterations are found in about half of patients with biliary tract cancer, with the highest incidence in intrahepatic cholangiocarcinoma, enabling targeted therapy.
Journals this month
Topics moving, week to 17 Nov 2026
By field